Incidence rate
(per 100 person-years)		   Hazard ratio
(95% CI)		 P value
NOAC Reference
Apixaban vs dabigatran (reference) n = 2373 n = 2373
 
    
Stroke/SE† 0.7 1.3
 
 0.51 (0.19-1.35) .175
Major bleeding‡ 3.9 5.6
 
 0.63 (0.44-0.90) .011
Apixaban vs rivaroxaban (reference) n = 7180 n = 7180
 
    
Stroke/SE† 1.3 1.3
 
 0.93 (0.68-1.26) .618
Major bleeding‡ 4.0 7.9
 
 0.47 (0.39-0.56) <.001
Dabigatran vs rivaroxaban (reference) n = 2617 n = 2617
 
    
Stroke/SE† 1.4 1.3
 
 1.13 (0.68-1.89) .629
Major bleeding‡ 5.4 6.7
 
 0.79 (0.61-1.03) .086
0.0
0.5
1.0
1.5
2.0
Favors comparator
Favors reference

No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs versus DOACs.

Appearance of plotted data may be altered when zoom greater than 150% is applied;
refer to values in tables for context when view is zoomed.

1|2|3|4|5